TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT03011814

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing Durvalumab, Laboratory Biomarker Analysis, and other medications against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 4 US locations.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Durvalumab (BIOLOGICAL): Given IV | Laboratory Biomarker Analysis (OTHER): Correlative studies | Lenalidomide (DRUG): Given PO

Drugs / treatments
Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is comparing Durvalumab, Laboratory Biomarker Analysis, and other medications against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 4 US locations.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Durvalumab (BIOLOGICAL): Given IV | Laboratory Biomarker Analysis (OTHER): Correlative studies | Lenalidomide (DRUG): Given PO

Drugs / treatments: Durvalumab, Laboratory Biomarker Analysis, Lenalidomide

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 78 patients

Primary endpoint: CTCL specific response assessed by Lugano Classification; Dose limiting toxicity assessed by CTCAE version 4.03; Duration of Complete Response; Event-Free Survival; Incidence of adverse events assessed by National Cancer Institute CTCAE version 4.03; Overall Response Rate (ORR); Overall survival (OS); Progression Free Survival (PFS); Response duration; Time to response

Ages: 18 Years to —

Start date: 2017-03-08 | Est. completion: 2026-08-30

Locations

4 US sites · 4 total

California, New York, Pennsylvania, Texas

Contact

—

Sponsor: City of Hope Medical Center (OTHER)

Tags

CTCL · PTCL-NOS · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT03011814

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.